NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
SBI Life to Consider Interim Dividend on Feb 25; Record Date Set for March 06, 2026
SBI Life Insurance Company has scheduled a board meeting on February 25, 2026, to deliberate on the declaration of an interim dividend for the financial year 2025-26. The company has proactively fixed March 06, 2026, as the record date to identify eligible shareholders for the potential payout. In compliance with insider trading regulations, the trading window for designated persons is closed from February 21 to February 27, 2026. This move indicates the company's intent to distribute surplus cash to its shareholders.
முக்கிய அம்சங்கள்
Board meeting scheduled for February 25, 2026, to consider interim dividend for FY 2025-26Record date for dividend eligibility fixed as March 06, 2026Trading window for insiders closed from February 21 to February 27, 2026The dividend amount will be determined during the upcoming board meeting
👀 கவனிக்க வேண்டியவை
Investors should watch for the dividend amount announcement on February 25 and ensure they hold shares before the ex-dividend date to qualify for the payout.
India Ratings Affirms BIL's Rating at IND BBB/Stable; Removes Negative Watch
India Ratings and Research (Ind-Ra) has affirmed the credit ratings for Bhartiya International Limited's bank loan facilities totaling INR 6,470.70 million. The agency assigned a long-term rating of 'IND BBB' with a Stable outlook and a short-term rating of 'IND A2'. Most significantly, the rating agency has removed the company from 'Rating Watch with Negative Implications' (RWN). This indicates a stabilization in the company's credit profile and a reduction in immediate financial risk factors.
முக்கிய அம்சங்கள்
Total bank loan facilities rated amount to INR 6,470.70 million.Long-term rating affirmed at 'IND BBB' with a 'Stable' outlook.Short-term rating affirmed at 'IND A2'.Successfully removed from 'Rating Watch with Negative Implications' (RWN), signaling improved credit stability.
👀 கவனிக்க வேண்டியவை
The removal of the negative watch is a positive signal for stakeholders, suggesting that the company's liquidity or operational concerns have stabilized. Investors should continue to monitor the company's debt levels and interest coverage ratios in upcoming quarterly reports.
SBI Life Receives Partial Relief in GST Case; Demand Reduced to ₹159.45 Crore
SBI Life Insurance has received an updated order from the GST appellate authority for FY 2018-19, providing partial relief. The total demand, which was previously ₹288.67 crore, has been reduced to ₹159.45 crore. This revised amount includes ₹63.36 crore in tax, ₹89.75 crore in interest, and ₹6.34 crore in penalty. The company has stated it will continue to contest the remaining demand by filing an appeal with the Appellate Tribunal.
முக்கிய அம்சங்கள்
Total tax demand for FY 2018-19 reduced by approximately 45% to ₹159.45 croreThe original demand of ₹288.67 crore was first disclosed in April 2024Key issues cited include ITC mismatches and non-reversal of credit on security transactionsSBI Life intends to file a further appeal against the partial demand upheld by the authority
👀 கவனிக்க வேண்டியவை
Monitor the progress of the appeal in the Appellate Tribunal; while the reduction is positive, the remaining liability is still noteworthy.
ABINFRA Q3 PAT Rises 16% YoY to ₹6.12 Cr; 9M Profit Surges 42%
A B Infrabuild Limited reported a steady performance for Q3 FY26, with Net Profit increasing by 16% YoY to ₹6.12 crore despite relatively flat revenue growth in the quarter. For the nine-month period ending December 2025, the company showed strong momentum, with revenue growing 26% to ₹172.27 crore and PAT surging 42% to ₹13.37 crore. The company successfully executed a 10:1 stock split in October 2025, which is reflected in the adjusted EPS. Operational efficiency appears to have improved as profit margins expanded significantly over the nine-month period.
முக்கிய அம்சங்கள்
Net Profit for Q3 FY26 grew 16% YoY to ₹6.12 crore from ₹5.27 crore in Q3 FY25.9M FY26 Revenue increased by 26.3% YoY to ₹172.27 crore compared to ₹136.42 crore in 9M FY25.9M FY26 PAT jumped 42.4% YoY to ₹13.37 crore against ₹9.39 crore in the previous year period.Earnings Per Share (EPS) for the nine-month period stood at ₹0.21 on a post-split basis (Face Value ₹1).Profit Before Tax (PBT) for 9M FY26 reached ₹18.08 crore, up from ₹12.79 crore in 9M FY25.
👀 கவனிக்க வேண்டியவை
The company demonstrates strong bottom-line growth and margin expansion, particularly over the 9-month horizon. Investors should monitor the sustainability of these margins and the company's ability to scale revenue in the upcoming final quarter of the fiscal year.
Concord Biotech Q3 FY26 Revenue Grows 14% to ₹278 Cr; API Segment Surges 24%
Concord Biotech reported a recovery in Q3 FY26 with revenue growing 14% YoY to ₹278 crores, though 9-month revenue remains 5% lower at ₹729 crores due to H1 disruptions. The API business was a major driver this quarter, growing 24% to ₹219 crores, while the formulation segment saw a decline. Reported EBITDA margins stood at 35.6%, impacted by start-up costs for the new injectable facility; however, core margins remain healthy at 40%. Management expects a return to historical growth levels in FY27 as regulatory hurdles clear and the injectable business scales toward its ₹600 crore peak potential.
முக்கிய அம்சங்கள்
Q3 FY26 revenue increased 14% YoY to ₹278 crores, led by strong API performance of ₹219 crores.Adjusted EBITDA margins (excluding start-up and US subsidiary costs) remained stable at 40%.The new injectable facility received WHO GMP certification, targeting a peak revenue of ₹600 crores.9-month PAT stood at ₹64 crores, impacted by ₹3 crores in new labor code provisions and lower other income.Company remains debt-free with cash and bank balances of ₹350 crores as of December 31, 2025.
👀 கவனிக்க வேண்டியவை
Investors should focus on the scale-up of the injectable facility and the resumption of Middle East tenders as primary growth drivers for FY27. The stock is a recovery candidate as temporary headwinds from H1 FY26, such as CDSCO delays and tariff uncertainties, have largely been resolved.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
BILVYAPAR Schedules 5th Committee of Creditors Meeting Under Insolvency Process
BIL Vyapar Limited, formerly known as Binani Industries Limited, has announced the 5th meeting of its Committee of Creditors (CoC). The company is currently undergoing a Corporate Insolvency Resolution Process (CIRP) following an NCLT order dated January 13, 2026. The affairs, business, and assets of the company are being managed by the Resolution Professional, Ms. Rachna Jhunjhunwala. This meeting is a critical step in the insolvency proceedings to determine the future of the company's debt and operations.
முக்கிய அம்சங்கள்
5th meeting of the Committee of Creditors (CoC) convened for BIL Vyapar Limited.Company is under Corporate Insolvency Resolution Process (CIRP) as per NCLT order dated January 13, 2026.Resolution Professional Ms. Rachna Jhunjhunwala is currently managing all company assets and affairs.Disclosure made in compliance with Regulation 30 and Para 16(g) of SEBI LODR Regulations.The company was formerly known as Binani Industries Limited before its name change.
👀 கவனிக்க வேண்டியவை
Investors should be extremely cautious as equity value is typically significantly impaired or wiped out during insolvency proceedings. Monitor upcoming disclosures regarding any submitted resolution plans or potential liquidation.
BirlaNu Limited, formerly HIL Limited, released its Q3 and 9M FY26 investor presentation detailing its strategic transformation and global footprint. The company operates 33 manufacturing facilities across India, Germany, and Austria, supported by a massive distribution network of 30,000+ retail points. With a vision to reach $1 billion in revenue, the company is diversifying across Pipes, Construction Chemicals, Putty, Roofs, Walls, and Floors. Digital engagement has seen a significant surge with 68 million interactions recorded in the first nine months of the fiscal year.
முக்கிய அம்சங்கள்
Maintains a global manufacturing presence with 33 units and a distribution network of 30,000+ retail points and 21,000+ channel partners.Installed capacities include 1.1 million MT for Roofs, 100k+ MTPA for Pipes, and 250k+ MTPA for Putty.Digital transformation efforts resulted in over 68 million views and interactions across platforms during 9M FY26.The company is part of the US$ 3 billion CKA Birla Group with a legacy of over 165 years.Strategic focus remains on the 'Vision $1 billion' goal through innovation, sustainability, and technology-led growth.
👀 கவனிக்க வேண்டியவை
Investors should track the company's transition from HIL to the BirlaNu brand and its impact on market share in the competitive building materials segment. Monitor the execution of the $1 billion revenue roadmap and the performance of the newly acquired Clean Coats business.
Emmbi Industries Q3 FY26 PAT Drops 34% YoY to ₹11.17 Mn Impacted by Exceptional Item
Emmbi Industries reported a 9.1% YoY growth in consolidated net sales for Q3 FY26, reaching ₹1,122.37 million. However, net profit (PAT) declined significantly by 34.3% YoY to ₹11.17 million, largely due to a one-time exceptional expense of ₹11.71 million for Labour Code compliance. On a sequential basis, revenue and profit both saw a decline compared to Q2 FY26. Despite the quarterly dip, the nine-month performance remains positive with PAT up 14.7% compared to the previous year.
முக்கிய அம்சங்கள்
Consolidated Net Sales grew 9.1% YoY to ₹1,122.37 million in Q3 FY26.Net Profit (PAT) fell 34.3% YoY to ₹11.17 million from ₹17.00 million in the previous year.A one-time exceptional provision of ₹11.71 million was recognized for compliance with new Labour Codes.9-Month FY26 Consolidated PAT stands at ₹54.61 million, a 14.7% growth over 9M FY25.Consolidated EPS for the quarter decreased to ₹0.58 from ₹0.94 in the year-ago period.
👀 கவனிக்க வேண்டியவை
The quarterly results are weak on the bottom line due to a one-time provision, though revenue growth remains stable YoY. Investors should watch for margin recovery in the next quarter to ensure operational costs are under control.
Tasty Bite Q3 FY26 PAT Surges 51% YoY; EBITDA Margins Expand to 18%
Tasty Bite Eatables reported a strong performance for the nine months ended December 2025, with PAT rising 51% YoY to ₹293 million. While YTD revenue growth was modest at 3%, the company saw a significant sequential revenue jump of 33% in Q3 FY26. Profitability improved sharply as EBITDA margins reached 18% in Q3, driven by operational efficiencies and a 128% growth in the Mars Affiliate business. Despite macroeconomic headwinds in the US consumer segment, the Food Service business maintained steady growth for the 9th consecutive quarter.
முக்கிய அம்சங்கள்
YTD PAT increased by 51% YoY to ₹293 million, aided by lower interest costs and higher EBITDA.Q3 FY26 EBITDA margin expanded to 18.0% from 10.4% in the preceding quarter.Mars Affiliate Business grew by 128% YTD, offsetting a 9% decline in other affiliate segments.Food Service Business (TFS) grew 16% YTD to ₹1,523 million, marking 9 consecutive quarters of growth.Company is pivoting towards Indian retail growth via Amazon and upcoming quick-commerce expansions.
👀 கவனிக்க வேண்டியவை
Investors should focus on the significant margin expansion and the company's ability to offset US market weakness through the Mars partnership. The successful scaling of the India retail and quick-commerce strategy will be the key catalyst for future valuation re-rating.
Tasty Bite Q3 PAT Drops 10.6% YoY to ₹84.3M; New Chairman Appointed
Tasty Bite Eatables reported a 4.8% YoY increase in revenue from operations to ₹1,340.54 million for the quarter ended December 31, 2025. However, Net Profit (PAT) declined by 10.6% YoY to ₹84.30 million, primarily due to higher operating expenses and a one-time exceptional charge. For the nine-month period, PAT also saw a decline to ₹283.47 million compared to ₹319.08 million in the previous year. The company also announced a significant leadership change, with Rahul Bhatnagar set to succeed Pradeep Poddar as Chairman in April 2026.
முக்கிய அம்சங்கள்
Revenue from operations grew 4.8% YoY to ₹1,340.54 million in Q3 FY26.Net Profit for the quarter fell to ₹84.30 million from ₹94.34 million in the same period last year.Recognized an exceptional item of ₹4.53 million as a provision for the New Labour Codes.9M FY26 PAT stands at ₹283.47 million, down from ₹319.08 million in 9M FY25.Chairman Pradeep Poddar to resign effective March 31, 2026; Rahul Bhatnagar appointed as successor.
👀 கவனிக்க வேண்டியவை
Investors should be cautious as the company is facing margin pressure despite stable revenue growth. Monitor the leadership transition and the impact of the New Labour Codes on future operating costs.
Gufic Bio Q3 Net Profit Declines 35% YoY to ₹12.4 Cr; Revenue Up 11% YoY
Gufic Biosciences reported a consolidated revenue of ₹231.4 crore for Q3 FY26, marking an 11.3% growth compared to the same quarter last year. However, net profit for the quarter fell sharply by 35.6% YoY to ₹12.4 crore, down from ₹19.3 crore in Q3 FY25. The profitability was primarily impacted by a significant rise in finance costs, which nearly doubled for the nine-month period to ₹27.2 crore. Additionally, the company announced a small strategic investment of up to USD 50,000 in Selvax Pty Ltd to acquire 3,78,350 ordinary shares.
முக்கிய அம்சங்கள்
Consolidated Revenue for Q3 FY26 stood at ₹231.4 crore, up 11.3% YoY but down 2.4% QoQ.Consolidated Net Profit for the quarter was ₹12.4 crore, a 35.6% decline from ₹19.3 crore in Q3 FY25.Finance costs for the nine-month period ended Dec 2025 surged to ₹27.2 crore from ₹14.7 crore YoY.9M FY26 Basic EPS dropped to ₹4.22 compared to ₹6.18 in 9M FY25.Board approved further investment in Selvax Pty Ltd at AUD 20 cents per share, totaling up to USD 50,000.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the company is facing significant margin pressure from rising interest and depreciation costs despite steady revenue growth. It is important to monitor the company's debt-servicing capability and the performance of its international subsidiaries.
Gufic Biosciences Targets 30% Indore Plant Utilization and EBITDA Breakeven in FY26
Gufic Biosciences has operationalized its advanced Indore facility as of October 2024, which features a monthly capacity of 5 million lyophilized vials and 6 million liquid vials. The company has already secured 203 product approvals for this facility and completed tech transfers for 40 products. Management expects the Indore unit to achieve EBITDA breakeven in FY26 at 30% utilization and become margin accretive by FY27. The strategic focus remains on high-growth platforms including Critical Care, Women's Health (IVF), and Botulinum Toxin (Aesthetics).
முக்கிய அம்சங்கள்
Indore facility monthly capacity includes 5 million lyophilized vials, 6 million liquid vials, and 10 million ampoules.Targeting 30% capacity utilization and EBITDA breakeven for the Indore facility during FY26.Received 203 product approvals from State FDA for the Indore unit with more in the pipeline.EU GMP and UK MHRA regulatory clearances for the new facility are targeted for Q1-FY27.Strong growth in specialized brands like Guficin Alpha in the Reproductive Immunology segment.
👀 கவனிக்க வேண்டியவை
Investors should track the quarterly utilization rates of the Indore facility and the progress of EU GMP/UK MHRA audits in early FY27 as these are key catalysts for export growth. The company's transition from a pure-play manufacturer to a specialized platform provider in aesthetics and IVF offers potential for long-term margin expansion.
BirlaNu Approves Merger of Clean Coats Subsidiary and Grants 1.10 Lakh ESOPs at Rs 1,803.80
BirlaNu Limited's board has approved the merger of its wholly-owned subsidiary, Clean Coats Private Limited, into the parent company to streamline operations and capture synergies in the construction chemicals segment. Clean Coats reported a turnover of Rs. 51.97 crore in FY25, while BirlaNu reported Rs. 2,310.04 crore. The board also approved the grant of 1,10,131 stock options to employees at an exercise price of Rs. 1,803.80 per share. Additionally, the financial results for the quarter ended December 31, 2025, were reviewed and approved by the board.
முக்கிய அம்சங்கள்
Approved the amalgamation of wholly-owned subsidiary Clean Coats Private Limited (FY25 turnover: Rs. 51.97 crore) with BirlaNu.No new shares will be issued for the merger as the transferor is a 100% subsidiary, resulting in no equity dilution.Granted 1,10,131 ESOPs at an exercise price of Rs. 1,803.80, with a two-tranche vesting schedule ending March 2028.The merger aims to reduce operational redundancies and optimize procurement and supply chain costs.Statutory auditors B S R and Co issued a clean limited review report on the Q3 FY26 financial results.
👀 கவனிக்க வேண்டியவை
Investors should view the merger as a positive step toward operational efficiency and business consolidation in the high-growth construction chemicals sector. The ESOP exercise price of Rs. 1,803.80 serves as a useful reference point for the company's internal valuation and management alignment.
BIL Vyapar Reports Q3 FY26 Results Amid Insolvency; Net Worth Eroded by ₹219 Crore
BIL Vyapar Limited (formerly Binani Industries) is currently undergoing Corporate Insolvency Resolution Process (CIRP) with its board powers suspended. The company reported accumulated losses of ₹21,906.99 lakhs as of December 31, 2025, resulting in a complete erosion of its net worth. Auditors have issued a disclaimer of opinion, noting that the financial statements are prepared on a liquidation basis rather than as a going concern. The company faces significant financial distress with liabilities exceeding assets by ₹18,768.50 lakhs.
முக்கிய அம்சங்கள்
Accumulated losses reached ₹21,906.99 lakhs with liabilities exceeding assets by ₹18,768.50 lakhs.Financial statements prepared on a liquidation basis as the 'going concern' assumption is no longer valid.Outstanding corporate guarantees of ₹8,025 lakhs and letters of comfort of ₹5,171.20 lakhs remain under dispute or litigation.Auditors issued a Disclaimer of Opinion due to multiple accounting discrepancies and the ongoing insolvency process.Statutory dues including GST and Income Tax have not been deposited due to the moratorium under IBC.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the company is in insolvency and equity value may be completely wiped out during the resolution process. The shift to liquidation-basis accounting indicates a high probability of total capital loss for retail shareholders.
BIL Vyapar Q3 Results: Net Worth Eroded, Liabilities Exceed Assets by ₹187.68 Crore
BIL Vyapar Limited (formerly Binani Industries) reported its Q3 FY26 results under the oversight of a Resolution Professional as the company is currently in the Corporate Insolvency Resolution Process (CIRP). The company's financial health is critical, with accumulated losses reaching ₹219.07 crore and a completely eroded net worth. Liabilities exceed total assets by ₹187.69 crore, leading the auditors to prepare accounts on a liquidation basis rather than a going concern. Furthermore, the auditors have issued a disclaimer of opinion due to multiple unresolved liabilities, including corporate guarantees totaling over ₹131 crore.
முக்கிய அம்சங்கள்
Accumulated losses stand at ₹21,906.99 lakhs as of December 31, 2025, with net worth fully eroded.Total liabilities exceed total assets by ₹18,768.50 lakhs, forcing the company to adopt a liquidation basis for accounting.Auditors issued a disclaimer of opinion due to significant uncertainties regarding corporate guarantees of ₹8,025 lakhs and ₹5,171.20 lakhs.The company is under a moratorium following the NCLT Kolkata Bench order dated November 21, 2025.Unrecorded losses of ₹33.51 lakhs on property sales and pending statutory dues were also highlighted by the auditors.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the company is in insolvency and the net worth is fully eroded, suggesting minimal residual value for equity shareholders. The shift to a liquidation basis for accounting indicates a very high risk of total capital loss.
Biofil Chemicals & Pharmaceuticals reported a severe decline in its financial performance for Q3 FY26, with revenue from operations crashing to ₹85.63 Lakhs from ₹1419.52 Lakhs in the same period last year. Net profit followed suit, dropping to ₹7.92 Lakhs compared to ₹16.46 Lakhs YoY. The company attributed this massive operational disruption to mandatory factory renovations and upgrades required to comply with the revised Schedule M of the Drugs & Cosmetics Rules. Consequently, the Chemicals division reported zero revenue for the quarter, while Pharma revenue saw a drastic reduction.
முக்கிய அம்சங்கள்
Revenue from operations fell by 94% YoY to ₹85.63 Lakhs from ₹1419.52 Lakhs.Net Profit for the quarter declined 51.9% YoY to ₹7.92 Lakhs.Chemicals division revenue dropped to zero for the quarter compared to ₹139.61 Lakhs in the preceding quarter.Manufacturing operations were partially disrupted due to factory renovation for Schedule M compliance.Earnings Per Share (EPS) halved to ₹0.05 from ₹0.10 in the corresponding quarter of the previous year.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the company's core manufacturing is currently hampered by facility upgrades; monitor for updates regarding the completion of renovations and the timeline for resuming full-scale production.
SBI Reports Record Q3 FY26 Net Profit of 21,028 Cr; Total Business Crosses 103 Trillion
State Bank of India (SBI) delivered a stellar Q3 FY26 performance, reporting its highest-ever quarterly net profit of 21,028 crore, a 24.49% YoY increase. The bank's total business surpassed the 103 trillion mark, driven by robust credit growth of 15.14% and a healthy deposit growth of 9.02%. Asset quality reached a two-decade high with Gross NPA at 1.57% and Net NPA at 0.39%, while the bank maintained a superior Return on Equity (ROE) of 20.68%. Management remains focused on digital transformation, with the new YONO platform gaining 3 crore registrations in just one month.
முக்கிய அம்சங்கள்
Highest-ever quarterly net profit of 21,028 crore, up 24.49% YoY, with operating profit rising 39.54% to 32,862 crore.Total credit growth of 15.14% YoY driven by a rebound in corporate credit (13.37%) and strong RAM segment performance.Asset quality improved significantly with Gross NPA at 1.57% (down 50 bps YoY) and Net NPA at 0.39% (down 14 bps YoY).Domestic Net Interest Margin (NIM) stood at 3.12%, while credit costs remained exceptionally low at 0.29%.Capital Adequacy Ratio (CAR) improved by 101 bps YoY to 14.04%, well above regulatory requirements.
👀 கவனிக்க வேண்டியவை
Investors should maintain a positive outlook on SBI as it demonstrates superior execution with record profitability and industry-leading asset quality. The bank's ability to sustain an ROA above 1% and an ROE over 20% at its massive scale makes it a preferred pick in the banking sector.
A B Infrabuild Limited Announces Q3 FY26 Financial Results
A B Infrabuild Limited has officially released its unaudited financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved the results in a meeting held on February 13, 2026, which concluded at 2:30 p.m. The independent auditor's report by Bhuwania & Agrawal Associates issued a clean limited review, confirming compliance with Indian Accounting Standards (Ind AS 34). While the specific financial figures were not detailed in the cover letter, the filing confirms the company's adherence to SEBI regulatory timelines.
முக்கிய அம்சங்கள்
Board approved unaudited financial results for the quarter and nine months ended December 31, 2025.Independent Auditor's Review Report issued with no material misstatements or qualifications.Financials prepared in accordance with Ind AS 34 and SEBI (LODR) Regulations, 2015.The board meeting was conducted between 1:00 p.m. and 2:30 p.m. on February 13, 2026.
👀 கவனிக்க வேண்டியவை
Investors should access the full financial tables on the stock exchange to analyze specific revenue and profit growth trends. Monitor the company's order book and execution capabilities in the infrastructure sector for long-term outlook.
Biocon Q3 FY26 Net Profit Surges 475% YoY to ₹144 Cr; Revenue Up 9%
Biocon reported a strong Q3 FY26 with consolidated revenue growing 9% YoY to ₹4,173 crore, driven by robust performance in Generics and Biosimilars. Reported Net Profit saw a massive 475% YoY jump to ₹144 crore, while Core EBITDA rose 21% YoY to ₹1,221 crore with margins improving to 29%. The Biosimilars segment grew 9% YoY with a significant 44% increase in EBITDA, although the CRDMO segment saw a slight 3% revenue decline due to transient customer challenges. The company is successfully managing debt leverage and focusing on high-growth areas like GLP-1 peptides.
முக்கிய அம்சங்கள்
Consolidated Revenue from Operations grew 9% YoY to ₹4,173 Cr.Reported Net Profit increased by 475% YoY to ₹144 Cr, while Core EBITDA rose 21% to ₹1,221 Cr.Generics segment revenue surged 24% YoY to ₹851 Cr, fueled by gLiraglutide launches in Europe.Biosimilars EBITDA grew 44% YoY to ₹700 Cr with a healthy 28% margin.CRDMO revenue declined 3% YoY to ₹917 Cr, though the BMS partnership was extended to 2035.
👀 கவனிக்க வேண்டியவை
Investors should monitor the margin expansion in Biosimilars and the commercial traction of the GLP-1 pipeline in the Generics segment. The successful deleveraging and transition to sustainable cash flow support a positive long-term outlook.
Ambica Agarbathies Q3 Net Profit Surges 197% YoY to ₹1.12 Crore
Ambica Agarbathies & Aroma Industries reported a strong performance for the quarter ended December 31, 2025, with total income rising 47% YoY to ₹55.23 crore. Net profit saw a significant jump of 197% YoY, reaching ₹1.12 crore compared to ₹0.38 crore in the same period last year. The growth was primarily driven by the Agarbathies division, which saw revenue increase to ₹46.61 crore. However, the Hotel division reported a marginal segment loss of ₹7.25 lakhs during the quarter.
முக்கிய அம்சங்கள்
Total Income increased 47% YoY to ₹55.23 crore from ₹37.56 crore.Net Profit grew by 197% YoY to ₹1.12 crore from ₹0.38 crore.Agarbathies division revenue surged to ₹46.61 crore from ₹29.18 crore YoY.Earnings Per Share (EPS) improved to ₹0.65 from ₹0.22 in the year-ago quarter.Nine-month (9M) net profit for FY26 reached ₹3.19 crore versus ₹2.42 crore in 9M FY25.
👀 கவனிக்க வேண்டியவை
Investors should monitor the continued growth in the core Agarbathies segment which is driving the bottom line, while keeping an eye on the Hotel division's return to profitability. The sharp YoY improvement in margins and EPS makes this a positive update for shareholders.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
